Skip to content
Home/Companies/Biotech/Delinia
DE

Delinia

Biotech·UK·Exited 2017·Held 1yr

Delinia is a healthcare / biotech company, headquartered in United Kingdom.

Entry
2016
Hold
1yr
Exit
2017
Est. EV
–

Who owns Delinia?

Delinia was owned by Sofinnova Partners through Sofinnova Capital VIII (2015 vintage) from 2016 to 2017, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VIII · 2015 · Life Sciences VC

Key facts

HQUnited Kingdom
SectorHealthcare / Biotech
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2017

More from Sofinnova Capital VIII

Other portfolio companies in the same fund.

VectivBio
Exited 2023
BiotechSwitzerland· 2017
to
Breath Therapeutics
Exited 2019
BiotechGermany· 2016
to
Corvidia Therapeutics
Exited 2020
BiotechUS· 2016
to
ENYO Pharma
Active
BiotechFrance· 2016
ReCor Medical
Exited 2018
MedTechUS· 2016
to
BiovelocITA
Active
BiotechItaly· 2015

More PE-backed in Biotech

Comparable biotech deals from other GPs.

InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
2NA FISH
Active
Gruenderfonds RuhrGermany· 2026
Data refreshed weekly · Sourced from public filings